



CPAL

Central Pennsylvania Alliance Laboratory

Technical Bulletin

No. 96

November 8, 2011

**KRAS and BRAF Mutation Assay
Additional Information Required
with Submitted Samples**

Contact:

Dr. Jeffrey Wisotzkey, 717-851-1422
Technical Director, CPAL

Jill Johns, MT(ASCP), SH, QCYM, 717-851-4320
Operations Manager, CPAL

Effective Date: 11/8/2011

Summary: Effective immediately an estimation of the neoplastic cell content of the selected “tumor” area **MUST** be indicated with specimens submitted for KRAS and/or BRAF mutational analysis. It is acceptable to indicate simply $\geq 50\%$ neoplastic cell content or $< 50\%$ neoplastic cell content. More specific estimates are acceptable.

Specimens in which no desired sampling area (tumor) and estimated neoplastic cell content is indicated will be returned to the client so that the proper region of interest and information can be indicated and resubmitted to CPAL.

Specimens should be transported and stored at room temperature.

Specific questions or concerns may be addressed to Dr. Wisotzkey

Issued on: November 8, 2011

For questions about this and other information, call Central Pennsylvania Alliance Laboratory at 1-888-480-1422.